Abstract
Abstract This study presents an evaluation of pemigatinib, a selective inhibitor of FGFR1-3, in the management of recurrent FGFR3 fusion glioblastoma, underlining its potential as a precision therapy. Introduced in a 53-year-old man after standard therapies failed and genomic profiling identified an FGFR3-TACC3 fusion, pemigatinib induced a partial disease response and neurological improvement but also posed a financial burden. The case emphasizes the role of precision medicine in neuro-oncology, and supports further research into the integration of pemigatinib into glioblastoma treatment protocols.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
